Source comparison
BPC-157 FDA Approved Status: Comparison Table
Understanding where BPC-157 fits in the regulatory landscape requires comparison to both approved pharmaceuticals and other research peptides. The table below shows how BPC-157's regulatory status compares to similar compounds across key regulatory and access
This comparison does not assign a generated winner or score.
- Understanding where BPC-157 fits in the regulatory landscape requires comparison to both approved pharmaceuticals and other research peptides. The table below shows how BPC-157's regulatory status compares to similar compounds across key regulatory and access dimensions.
- | Compound | FDA Approval Status | Legal Classification | Prescription Required | Clinical Trial Data | Regulatory Pathway | Bottom Line ||—|—|—|—|—|—|| BPC-157 | Not approved; no IND application filed | Research peptide | No (not prescribable) | Animal studies only; no Phase I–III human trials | No active pathway to approval | Legal for research purchase; not approved or intended for human therapeutic use || Semaglutide (Ozempic/Wegovy) | FDA approved 2017 (diabetes), 2021 (weight loss) | Prescription pharmaceutical | Yes | Phase I–III completed; ongoing post-market surveillance | Completed NDA pathway | Approved drug with established safety/efficacy; compounded versions legal under shortage provisions || TB-500 (Thymosin Beta-4 fragment) | Not approved; studied under IND for specific indications | Research peptide | No (not prescribable) | Limited Phase I/II data in wound healing; mostly animal studies | No active commercial pathway | Similar regulatory position to BPC-157; research-